



(12) **United States Patent**  
**Fujiki et al.**

(10) **Patent No.:** **US 9,636,382 B2**  
(45) **Date of Patent:** **May 2, 2017**

(54) **DRUG FOR PREVENTING AND/OR  
TREATING POLYCYSTIC KIDNEY DISEASE**

(71) Applicant: **OTSUKA PHARMACEUTICAL CO.,  
LTD.**, Chiyoda-ku, Tokyo (JP)

(72) Inventors: **Hiroyuki Fujiki**, Osaka (JP); **Miki  
Aihara**, Osaka (JP); **Shizuo Kinoshita**,  
Osaka (JP)

(73) Assignee: **OTSUKA PHARMACEUTICAL CO.,  
LTD.**, Tokyo (JP)

(\*) Notice: Subject to any disclaimer, the term of this  
patent is extended or adjusted under 35  
U.S.C. 154(b) by 0 days.

(21) Appl. No.: **14/402,540**

(22) PCT Filed: **May 30, 2013**

(86) PCT No.: **PCT/JP2013/065637**

§ 371 (c)(1),

(2) Date: **Nov. 20, 2014**

(87) PCT Pub. No.: **WO2013/180310**

PCT Pub. Date: **Dec. 5, 2013**

(65) **Prior Publication Data**

US 2015/0141338 A1 May 21, 2015

**Related U.S. Application Data**

(60) Provisional application No. 61/653,524, filed on May  
31, 2012.

(51) **Int. Cl.**

**A61K 38/31** (2006.01)

**A61K 31/55** (2006.01)

**A61K 9/00** (2006.01)

(52) **U.S. Cl.**

CPC ..... **A61K 38/31** (2013.01); **A61K 9/0019**  
(2013.01); **A61K 9/0053** (2013.01); **A61K**  
**31/55** (2013.01)

(58) **Field of Classification Search**

CPC ..... **A61K 9/0019**; **A61K 38/31**; **A61K 31/55**;  
**A61K 9/0053**; **A61K 2300/00**

See application file for complete search history.

(56) **References Cited**

**FOREIGN PATENT DOCUMENTS**

JP 4-154765 A 5/1992  
WO 91/05549 A1 5/1991  
WO 2005/000893 A2 1/2005

**OTHER PUBLICATIONS**

Torres, Vasopressin antagonists in polycystic kidney disease, Semi-  
nars in Nephrology, 2008, 28, pp. 306-317.\*

Polycystic Kidney Disease, from <http://www.niddk.nih.gov/health-information/health-topics/kidney-disease/polycystic-kidney-disease-pkd/Pages/facts.aspx>, pp. 1-16, accessed Oct. 19, 2015.\*

Tallarida, Drug synergism and dose-effect data analysis, CRC Press  
LLC, 2000, pp. 1-29.\*

Marie C. Hogan, et al., "Randomized Clinical Trial of Long-Acting  
Somatostatin for Autosomal Dominant Polycystic Kidney and Liver  
Disease", Journal of the American Society of Nephrology, Jun.  
2010, pp. 1052-1061, vol. 21, No. 6.

Vishal Patel, et al., "Advances in the Pathogenesis and Treatment of  
Polycystic Kidney Disease", Current Opinion in Nephrology and  
Hypertension, Mar. 2009, pp. 99-106, vol. 18, No. 2.

Vincent E. Torres, "Role of Vasopressin Antagonists", Clinical  
Journal of the American Society of Nephrology, Apr. 2008, pp.  
1212-1218, vol. 3, No. 4.

Tatyana V. Masyuk, et al., "Pasireotide is More Effective than  
Octreotide in Reducing Hepatorenal Cystogenesis in Rodents with  
Polycystic Kidney Liver Diseases", Hepatology, pp. 409-421, vol.  
58, No. 1, Jul. 2013.

Vincent H. Gattone II, et al., "Inhibition of renal cystic disease  
development and progression by a vasopressin V2 receptor antago-  
nist", Nature Medicine, Oct. 2003, pp. 1323-1326, vol. 9, No. 10.  
Xiaofang Wang, et al., "Effectiveness of Vasopressin V2 Receptor  
Antagonists OPC-31260 and OPC-41061 on Polycystic Kidney  
Disease Development in the PCK Rat", J. Am. Soc. Nephrol., 2005,  
pp. 846-851, vol. 16.

International Search Report for PCT/JP2013/065637 dated Aug. 20,  
2013 [PCT/ISA/210].

Written Opinion for PCT/JP2013/065637 dated Aug. 20, 2013  
[PCT/ISA/237].

Tatyana V. Masyuk, et al., "Pasireotide is More Effective than  
Octreotide in Reducing Hepatorenal Cystogenesis in Rodents with  
Polycystic Kidney and Liver Diseases", Hepatology, Jul. 2013, pp.  
409-421, vol. 58, No. 1.

Vincent H. Gattone II et al., "Novel Therapies for Polycystic Kidney  
Disease," Genetic Syndromes & Gene Therapy, 2011, S:4, pp. 1-9.  
"The comparison between Somatostatin and Octreotide," retrieved  
from [http://mulicia.pixnet.net/blog/post/21531460-somatostatin-%E8%88%87octreotide%](http://mulicia.pixnet.net/blog/post/21531460-somatostatin-%E8%88%87octreotide%20), on Oct. 13, 2016, pp. 1-9.

Chang, M., et al., "Mechanism-Based Therapeutics for Autosomal  
Dominant Polycystic Kidney Disease: Recent Progress and Future  
Prospects", Nephron Clinical Practice, 2012, vol. 120, No. 1, pp.  
c25-c35.

Zmily, H., et al., "Tolvaptan, hyponatremia, and heart failure",  
International Journal of Nephrology and Renovascular Disease,  
2011, vol. 4, pp. 57-71.

Communication, dated Jan. 31, 2017, issued by the Japanese Patent  
Office in counterpart Japanese Patent Application No. 2014-555000.

\* cited by examiner

Primary Examiner — Julie Ha

Assistant Examiner — Li Ni Komatsu

(74) Attorney, Agent, or Firm — Sughrue Mion, PLLC

(57) **ABSTRACT**

An object of the present invention is to provide a combina-  
tion drug that has remarkably excellent preventive and/or  
therapeutic effects on polycystic kidney disease. The present  
invention provides a drug for preventing and/or treating  
polycystic kidney disease comprising a combination of  
tolvaptan or a prodrug thereof with a somatostatin deriva-  
tive, and a method for treating polycystic kidney disease  
using this drug.

**4 Claims, No Drawings**